The Journal of Urology
Volume 179, Issue 2 , Pages 743-747 , February 2008

Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer

  • Mohammad Obaidul Hoque

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationCorrespondence: Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans St., CRB II, 5N.03, Baltimore, Maryland 21231 (telephone: 410-502-5153 or 410-502-8778; FAX: 410-614-1411).
    • Financial interest and/or other relationship with GlaxoSmithKline, Elsevier, Teng, Viventia and Pfizer.
    • ,
  • Shahnaz Begum

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Mariana Brait

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Carmen Jeronimo

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Marianna Zahurak

      Affiliations

    • Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Kimberly Laskie Ostrow

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Eli Rosenbaum

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Bruce Trock

      Affiliations

    • The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • William H. Westra

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Mark Schoenberg

      Affiliations

    • The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • ,
  • Steven N. Goodman

      Affiliations

    • Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • David Sidransky

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationCorrespondence: Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1550 Orleans St., CRB II, 5N.03, Baltimore, Maryland 21231 (telephone: 410-502-5153 or 410-502-8778; FAX: 410-614-1411).
    • Financial interest and/or other relationship with Oncomethylome Sciences.

Received 23 December 2005

References 

  1. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666
  2. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998;160:645
  3. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2:210
  4. Jones PA. DNA methylation and cancer. Oncogene. 2002;21:5358
  5. Airola K, Ahonen M, Johansson N, Heikkila P, Kere J, Kahari VM, et al. Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. J Histochem Cytochem. 1998;46:437
  6. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998;58:2310
  7. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis. 1996;17:1805
  8. Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer. 1997;75:1678
  9. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 2003;63:2216
  10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821
  11. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003;9:1370
  12. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006;98:996
  13. Hoque MO, Lee J, Begum S, Yamashita K, Engles JM, Schoenberg M, et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res. 2003;63:5723
  14. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912
  15. Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E, et al. PUMA in head and neck cancer. Cancer Lett. 2003;199:75
  16. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859
  17. Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202:395
  18. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798
  19. Yu WH, Yu S, Meng Q, Brew K, Woessner JF. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000;275:31226
  20. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407

 Study received approval from The Johns Hopkins Hospital institutional review board.Supported by National Cancer Institute Grant U01-CA84986, Oncomethylome Sciences, SA, a Young Clinical Scientist Award from the Flight Attendant Medical Research Institute (MOH) and a Young Investigator Award from the International Association for the Study of Lung Cancer (MOH).

PII: S0022-5347(07)02490-1

doi: 10.1016/j.juro.2007.09.019

The Journal of Urology
Volume 179, Issue 2 , Pages 743-747 , February 2008

Article Tools

* Image Usage & Resolution